TY  - JOUR
A1  - Falkenbach, Fabian
A1  - Lischewski, Flemming
A1  - Knipper, Sophie
A1  - Koehler, Daniel
A1  - Karakiewicz, Pierre I.
A1  - Tian, Zhe
A1  - Saad, Fred
A1  - Tilki, Derya
A1  - Budäus, Lars
A1  - Steuber, Thomas
A1  - Mandel, Philipp
A1  - Wenzel, Mike
A1  - Gschwend, Jürgen E.
A1  - Graefen, Markus
A1  - Heck, Matthias M.
A1  - Maurer, Tobias
T1  - Prostate-specific membrane antigen–radioguided surgery in an EMBARK-like cohort of patients with oligorecurrent hormone-sensitive prostate cancer: delay in systemic treatment
T2  - European Urology Focus
N2  - We analyzed data for a cohort of 111 patients with EMBARK-like biochemical recurrence (BCR) of prostate cancer (prostate-specific antigen [PSA] doubling time ≤9 mo, PSA ≥1 ng/ml) after radical prostatectomy and localized oligorecurrence on prostate-specific membrane antigen (PSMA)-based imaging. All patients underwent PSMA-radioguided surgery (RGS). At PSMA-RGS, the median PSA was 1.95 ng/ml (interquartile range [IQR] 1.36–3.20) ng/ml and the median PSA doubling time was 4.0 mo (IQR 2.5–5.5). Clavien-Dindo grade >IIIa complications occurred in nine of 111 patients (8.1%). A complete biochemical response (cBR; PSA decline ≤0.2 ng/ml after PSMA-RGS) was observed in 53 patients (47.7%). In the cBR group (equivalent to the treatment suspension criterion in EMBARK), estimated survival rates at 2 yr were 49.9% (95% confidence interval [CI] 37.2–67.1%) for BCR-free survival and 65.2% (95% CI 52.2–81.4%) for treatment-free survival. A relevant proportion of our PSMA-RGS cohort with localized oligorecurrence on PSMA-based imaging fulfilled the EMBARK criteria. PSMA-RGS yielded meaningful biochemical responses that translated to long-lasting treatment-free periods.
Y1  - 2025
UR  - https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/124374
SN  - 2405-4569
PB  - Elsevier BV
ER  -